Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board:...
Transcript of Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board:...
![Page 2: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/2.jpg)
Disclosures
Speakers Bureau: Janssen, Roche, Takeda, Abbvie, BMS
Educational Support: Janssen, Takeda, Roche, Abbvie
Advisory Board: Janssen, Abbvie, Astra Zeneca
Research: Janssen, Millenium, Merck, Alnylam
Slides will be presented in English for better comprehension of invitedspeakers
![Page 3: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/3.jpg)
Questions to be adressed
• What should be our goal in FL?
• What does longer follow up of studies tells us about Rituximabmaintenance?
• Does induction chemo influences maintenance results?
• Are new MoAbs suitable for Maintenance?
• How safe is maintenance?
![Page 4: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/4.jpg)
What should be our goal
in FL?
![Page 5: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/5.jpg)
What should be our goal in FL?
56 y/o patient
Stage IIIB FL
6x R-CHOP, denied RM
EOT PET: residual 3cm lymph node
1y: Abd CT shows a 5cm lymph node
4 years later, B-symptoms
4x R: PR
Denied again MR
6y: Multiple LFN, assymptomatic
76 y/o patient
Stage IVA FL
6x R-CHOP + RM
EOT PET: PR
6m – PET : CR
RM 14 month: Herpes Zoster
Postherpetic neuralgia requiring opioids
2y: CR
Opioid abuse?
2.5y: Aspiration PNM due to opiod abuse
- 13days in ICU
- 24 days inpatient
3y: CR, PS 2
![Page 6: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/6.jpg)
What should be our goal in FL?
56 y/o patient
Stage IIIB FL
6x R-CHOP, denied RM
EOT PET: residual 3cm lymph node
1y: Abd CT shows a 5cm lymph node
4 years later, B-symptoms
4x R: PR
Denied again MR
6y: Multiple LFN, assymptomatic
76 y/o patient
Stage IVA FL
6x R-CHOP + RM
EOT PET: PR
6m – PET : CR
RM 14 month: Herpes Zoster
Postherpetic neuralgia requiring opioids
2y: CR
Opioid abuse?
2.5y: Aspiration PNM due to opiod abuse
- 13days in ICU
- 24 days inpatient
3y: CR
PFS Event: 1yTTNT: 4yOS Event: None
PFS Event: NoneTTNT: NoneOS Event: None
![Page 7: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/7.jpg)
What should be our goal in FL?
First, do no harm.
PFS is a goal for some patients
Safety is a goal for others
OS is a goal for ALL patients
Talk to your patients. Reevaluate your decisions. Avoid regret.
![Page 8: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/8.jpg)
What does longer follow up of studies tellsus about Rituximab maintenance?
![Page 9: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/9.jpg)
Maintenance in R/R FL: EORTC 20981
Van Oers, JCO 2010
![Page 10: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/10.jpg)
EORCT 20981: 6y F/U
Van Oers, JCO 2010
![Page 11: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/11.jpg)
![Page 12: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/12.jpg)
![Page 13: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/13.jpg)
![Page 14: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/14.jpg)
![Page 15: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/15.jpg)
![Page 16: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/16.jpg)
![Page 17: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/17.jpg)
![Page 18: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/18.jpg)
Major Causes of death in PRIMA – 10y update
Cause of death Observation R-Maintenance
Lymphoma 38 39
Malignancies 24 6
Myeloid 7 2
Infection 6 11
Cardiovascular 4 8
TTNT: 6.1 years Obs x NR in the R-maintenance arm (P<.0001; HR=0.66; 95%CI 0.55-0.78)
10-year Free from treatment: 53% x 41%
![Page 19: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/19.jpg)
What about retreatment? RESORT Study
Median R doses:
RR: 4MR: 18
Khal B, JCO 2014
![Page 20: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/20.jpg)
Resort Study
Khal B, JCO 2014
![Page 21: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/21.jpg)
RESORT Study
Khal B, JCO 2014
![Page 22: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/22.jpg)
Beware of Comparisons!
PRIMA RESORT
Tumor Burden High Low
Induction R-Chemo R-single agent
Depth of response after induction +++ +
Follow up 10 4.5
![Page 23: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/23.jpg)
Does induction chemo influencesMaintenance?
![Page 24: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/24.jpg)
STIL Study
![Page 25: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/25.jpg)
STIL 10 y Follow up
![Page 26: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/26.jpg)
Still 10y OS
![Page 27: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/27.jpg)
BRIGHT Study
R-Maintenanceby investigators’discretion
![Page 28: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/28.jpg)
BRIGHT Study – DOR
![Page 29: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/29.jpg)
BRIGHT Study – OS
![Page 30: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/30.jpg)
![Page 31: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/31.jpg)
MAINTAIN Study – 2 x 4y RM after BR
Rummel et al, Blood 2017
![Page 32: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/32.jpg)
MAINTAIN – PFS RM 2 x 4y
Rummel et al, Blood 2017
![Page 33: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/33.jpg)
MAINTAIN – OS from Randomization
Rummel et al, Blood 2017
![Page 34: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/34.jpg)
STIL x Maintain: PFS
![Page 35: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/35.jpg)
STIL x MAINTAIN: No OS Benefit
![Page 36: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/36.jpg)
Conclusions
• Chemo backbone impacts the benefit of RM• All groups benefit in PFS
• No benefit after BR in OS
• Trend for OS benefit in R-CHOP/R-CVP
• BR patients achieving CR• No Benefit in MR
• Retrospective registry study
• Toxicity is also impacted
![Page 37: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/37.jpg)
Are new MoAbs suitable for Maintenance?
![Page 38: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/38.jpg)
GALLIUM Study
![Page 39: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/39.jpg)
Only the UK Likes R-CVP
![Page 40: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/40.jpg)
Response after induction (FL)
![Page 41: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/41.jpg)
PFS: R x G
![Page 42: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/42.jpg)
PFS for FL: R x G
![Page 43: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/43.jpg)
TTNT (FL): R x G
![Page 44: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/44.jpg)
OS (FL): G x R
![Page 45: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/45.jpg)
How safe is maintenance?
![Page 46: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/46.jpg)
How Safe is Maintenance?
Pretty Safe!
With Rituximab
• 7%+ events on PRIMA
• More Grade 3 Events (infections)
• No safety signal after 10 years of PRIMA
![Page 47: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/47.jpg)
Gallium Safety analysis
![Page 48: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/48.jpg)
G-Bendamustine particularlyproblematic
![Page 49: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/49.jpg)
![Page 50: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/50.jpg)
IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN a SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL)
![Page 51: Should all patients with FL receive maintenance therapy? · 2020. 12. 23. · Advisory Board: Janssen, Abbvie, Astra Zeneca Research: Janssen, Millenium, Merck, Alnylam Slides will](https://reader035.fdocuments.in/reader035/viewer/2022071610/6149709b080bfa6260149c7b/html5/thumbnails/51.jpg)
Conclusions
• Not all patients should receive Maintenance after Induction• Patient informed and centered-decision• >80% decide for R-Maintenance and I am OK with it
• Dont push your patient too hard• Its OK to STOP Maintenance if toxicity• You are NOT avoiding LYMPHOMA DEATHS with Maintenance (PRIMA)
• I dont use RM after BR• I avoid GB in first line therapy, especially in older patients• I will not use GM after GB in first line therapy of FL• I have used GM after GB in second-line therapy in some patients